However, that is not the reality: even diabetic patients treated with GLP-1 RAs are more likely to stop them than other second-line anti-diabetic medicines
For many patients, there is a transition: Phase 1: Correct Improve insulin resistance Reduce inflammation Initiate weight loss Phase 2: Stabilize Support muscle and metabolism Begin lowering the dose Phase 3: Maintain / Optimize Lower-dose or microdosing approach (when appropriate) Focus on long-term metabolic health At lower doses, GLP-1 medications may continue to support the bodynot just for weight loss, but for overall metabolic function
Bahmyari R, Zare M, Sharma R, Agarwal A, Halvaei I
Thank you for the information
The GLP-1 drug lixisenatide, for instance, seemed to offer some slight protection from worsening Parkinsons disease symptoms, researchers reported in 2024 in the New England Journal of Medicine
Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse
.png)
